Hudson Bay Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$95.6M Buy
+380,000
New +$81.8M 0.26% 88
2025
Q3
– Sell
-56,200
Closed -$10.4M – 1203
2025
Q2
$10.4M Sell
56,200
-647,700
-92% -$120M 0.04% 348
2025
Q1
$147M Buy
+703,900
New +$137M 0.45% 48
2024
Q2
– Sell
-200,000
Closed -$36.4M – 761
2024
Q1
$36.4M Buy
+200,000
New +$34.5M 0.2% 68
2017
Q2
– Sell
-50,000
Closed -$3.26M – 514
2017
Q1
$3.26M Buy
50,000
+25,000
+100% +$1.57M 0.04% 353
2016
Q4
$1.57M Buy
+25,000
New +$1.53M 0.03% 399

Other funds holding ABBV

Hudson Bay Capital Management's ABBV Position: Q2 2026 in Review

Hudson Bay Capital Management increased its AbbVie (ABBV) stake by 1,911% in Q2 2026, buying an estimated $82.3M and bringing the position to 402,440 shares worth $101M. The position accounts for 0.28% of the portfolio, ranked #83.

Hudson Bay Capital Management first reported a position in ABBV in Q3 2014 and has held it in 16 quarters since. The position peaked at $136M in Q1 2025. 4,232 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Hudson Bay Capital Management held 402,440 shares of AbbVie worth $101M as of Q2 2026.
  • Hudson Bay Capital Management bought 382,430 AbbVie shares in Q2 2026, an estimated $82.3M.
  • AbbVie made up 0.28% of Hudson Bay Capital Management's portfolio in Q2 2026, its #83 holding.
  • Hudson Bay Capital Management first reported a position in AbbVie in Q3 2014 and has held it in 16 quarters since.
  • Hudson Bay Capital Management's AbbVie position peaked at $136M in Q1 2025.
  • 4,232 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.